Basic Information
| RNALocate ID: | RLID:11002794 |
| RNA Symbol: | hsa-miR-200a-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-200a-5p |
| RNA ID: | miRBase:MIMAT0001620 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 22211110 |
| Tissue/Cell Line: | Breast milk |
| Method: | Next-generation RNA sequencing |
|
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
| Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:11002792 | Exosome | Peripheral blood | 31746410 |
| RLID:11002793 | Exosome | B cell line (Raji)|Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11002795 | Exosome | Brain tissue | 23382797 |
| RLID:11002796 | Exosome | Plasma | 23663360 |
| RLID:11002797 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000140 | Exosome | Colon tissue|Tongue tissue | |
| RLID-D:11000456 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-200a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-25945 |
| MNDR | hsa-miR-200a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-25946 |
| MNDR | hsa-miR-200a-5p | Ovarian clear cell carcinoma | MNDR-E-MI-25947 |
| MNDR | hsa-miR-200a-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-25948 |
| MNDR | hsa-miR-200a-5p | Lymphoma | MNDR-E-MI-25949 |
| MNDR | hsa-miR-200a-5p | Prostate cancer | MNDR-E-MI-25950 |
| MNDR | hsa-miR-200a-5p | Gastric cancer | MNDR-E-MI-25951 |
| MNDR | hsa-miR-200a-5p | Bladder cancer | MNDR-E-MI-25952 |
| MNDR | hsa-miR-200a-5p | Parkinson disease | MNDR-E-MI-25953 |
| MNDR | hsa-miR-200a-5p | Breast cancer | MNDR-E-MI-25954 |
| MNDR | hsa-miR-200a-5p | Thyroid cancer | MNDR-E-MI-25955 |
| MNDR | hsa-miR-200a-5p | Pituitary neoplasms | MNDR-E-MI-25956 |
| MNDR | hsa-miR-200a-5p | Pancreatic cancer | MNDR-E-MI-25957 |
| MNDR | hsa-miR-200a-5p | Rectum adenocarcinoma | MNDR-E-MI-25958 |
| MNDR | hsa-miR-200a-5p | Nephroblastoma | MNDR-E-MI-25959 |
| MNDR | hsa-miR-200a-5p | Colon cancer | MNDR-E-MI-25960 |
| MNDR | hsa-miR-200a-5p | Colon adenocarcinoma | MNDR-E-MI-25961 |
| MNDR | hsa-miR-200a-5p | Familial ovarian cancer | MNDR-E-MI-25962 |
| MNDR | hsa-miR-200a-5p | Carcinoma ductal breast | MNDR-E-MI-25963 |
| MNDR | hsa-miR-200a-5p | Invasive ductal carcinoma | MNDR-E-MI-25964 |
| MNDR | hsa-miR-200a-5p | Glioma | MNDR-E-MI-25965 |
| MNDR | hsa-miR-200a-5p | Breast carcinoma | MNDR-E-MI-25966 |
| MNDR | hsa-miR-200a-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-25967 |
| MNDR | hsa-miR-200a-5p | Cervical adenocarcinoma | MNDR-E-MI-25968 |
| MNDR | hsa-miR-200a-5p | Gastric adenocarcinoma | MNDR-E-MI-25969 |
| MNDR | hsa-miR-200a-5p | Cervical squamous cell carcinoma | MNDR-E-MI-25970 |
| MNDR | hsa-miR-200a-5p | Pituitary adenoma | MNDR-E-MI-25971 |
| MNDR | hsa-miR-200a-5p | Lung squamous cell carcinoma | MNDR-E-MI-25972 |
| MNDR | hsa-miR-200a-5p | Lung adenocarcinoma | MNDR-E-MI-25973 |
| MNDR | hsa-miR-200a-5p | Ovarian carcinoma | MNDR-E-MI-25974 |
| MNDR | hsa-miR-200a-5p | Bladder urothelial carcinoma | MNDR-E-MI-25975 |
| MNDR | hsa-miR-200a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-25976 |
| MNDR | hsa-miR-200a-5p | Carcinoma renal cell | MNDR-E-MI-25977 |
| MNDR | hsa-miR-200a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-25978 |
| MNDR | hsa-miR-200a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-25979 |
| MNDR | hsa-miR-200a-5p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-25980 |
| MNDR | hsa-miR-200a-5p | Cholangiocarcinoma | MNDR-E-MI-25981 |
| MNDR | hsa-miR-200a-5p | Lung small cell carcinoma | MNDR-E-MI-25982 |
| MNDR | hsa-miR-200a-5p | Synovial sarcoma | MNDR-E-MI-25983 |
| MNDR | hsa-miR-200a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-25984 |
| MNDR | hsa-miR-200a-5p | Testicular germ cell cancer | MNDR-E-MI-25985 |
| MNDR | hsa-miR-200a-5p | Breast invasive carcinoma | MNDR-E-MI-25986 |
| MNDR | hsa-miR-200a-5p | Hepatocellular carcinoma | MNDR-E-MI-25987 |
| MNDR | hsa-miR-200a-5p | Familiar ovarian carcinoma | MNDR-E-MI-25988 |
| MNDR | hsa-miR-200a-5p | Barrett's adenocarcinoma | MNDR-E-MI-25989 |
| MNDR | hsa-miR-200a-5p | Tonsil cancer | MNDR-E-MI-25990 |
| MNDR | hsa-miR-200a-5p | Skin cutaneous melanoma | MNDR-E-MI-25991 |
| MNDR | hsa-miR-200a-5p | Skin melanoma | MNDR-E-MI-25992 |
| MNDR | hsa-miR-200a-5p | Colorectal cancer | MNDR-E-MI-25993 |
| MNDR | hsa-miR-200a-5p | Barrett's carcinogenesis | MNDR-E-MI-25994 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CTNNB1 | Homo sapiens | RR00378128 |
TOP